MIRA Pharmaceuticals, Inc. (MIRA)

Develops therapies for dermatological and autoimmune diseases, focusing on novel treatments and topical formulations.

MIRA Stock Quote

Company Report

MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company focused on advancing treatments for neurologic and neuropsychiatric disorders through two pioneering neuroscience programs.

One of its key innovations is Ketamir-2, an oral ketamine analog with exclusive rights in the U.S., Canada, and Mexico. Ketamir-2 is currently in development to offer rapid antidepressant effects, targeting conditions such as treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.

Additionally, MIRA Pharmaceuticals is exploring the therapeutic potential of MIRA-55, an oral pharmaceutical marijuana formulation aimed at alleviating anxiety and cognitive decline in adult patients, particularly those experiencing early-stage dementia.

Founded in 2020 and headquartered in Miami, Florida, MIRA Pharmaceuticals, Inc., formerly known as MIRA1a Therapeutics, Inc., continues to drive innovation in pharmaceutical research and development, with a strong commitment to addressing significant unmet medical needs in neurology and psychiatry.

MIRA EPS Chart

MIRA Revenue Chart

Stock Research

FCBC ITT LPCN CIEN AMNB JOUT APP

MIRA Chart

View interactive chart for MIRA

MIRA Profile

MIRA News

Analyst Ratings